Voloridge Investment Management LLC Purchases New Holdings in bluebird bio Inc (BLUE)

Share on StockTwits

Voloridge Investment Management LLC purchased a new position in shares of bluebird bio Inc (NASDAQ:BLUE) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 55,104 shares of the biotechnology company’s stock, valued at approximately $5,466,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BLUE. Capital International Investors increased its holdings in shares of bluebird bio by 188.6% during the 3rd quarter. Capital International Investors now owns 3,260,636 shares of the biotechnology company’s stock worth $476,053,000 after buying an additional 2,130,927 shares during the last quarter. Capital World Investors increased its holdings in bluebird bio by 37.4% in the 3rd quarter. Capital World Investors now owns 3,425,687 shares of the biotechnology company’s stock valued at $500,150,000 after purchasing an additional 931,932 shares during the last quarter. FMR LLC increased its holdings in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 8,123,687 shares of the biotechnology company’s stock valued at $1,186,058,000 after purchasing an additional 605,797 shares during the last quarter. Capital Research Global Investors increased its holdings in bluebird bio by 8.1% in the 3rd quarter. Capital Research Global Investors now owns 6,634,317 shares of the biotechnology company’s stock valued at $968,610,000 after purchasing an additional 494,787 shares during the last quarter. Finally, Vanguard Group Inc increased its holdings in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after purchasing an additional 422,866 shares during the last quarter.

Several analysts recently weighed in on the stock. ValuEngine upgraded shares of bluebird bio from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Leerink Swann downgraded shares of bluebird bio from an “outperform” rating to a “market perform” rating and set a $150.00 target price for the company. in a report on Tuesday, March 5th. They noted that the move was a valuation call. Cowen assumed coverage on shares of bluebird bio in a report on Tuesday, February 26th. They issued an “outperform” rating and a $149.91 target price for the company. Svb Leerink downgraded shares of bluebird bio from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Finally, Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Monday, February 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. bluebird bio has a consensus rating of “Buy” and a consensus price target of $168.12.

In other news, insider David Davidson sold 7,600 shares of bluebird bio stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $98.82, for a total transaction of $751,032.00. Following the completion of the sale, the insider now directly owns 15,559 shares of the company’s stock, valued at approximately $1,537,540.38. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Nick Leschly sold 7,374 shares of bluebird bio stock in a transaction on Monday, January 7th. The stock was sold at an average price of $113.64, for a total transaction of $837,981.36. Following the sale, the insider now directly owns 20,682 shares of the company’s stock, valued at $2,350,302.48. The disclosure for this sale can be found here. Insiders sold a total of 42,438 shares of company stock valued at $5,486,744 in the last three months. 3.00% of the stock is currently owned by corporate insiders.

BLUE stock traded down $3.44 during midday trading on Friday, hitting $152.74. The company’s stock had a trading volume of 3,576 shares, compared to its average volume of 612,370. bluebird bio Inc has a 52-week low of $87.49 and a 52-week high of $199.70. The stock has a market capitalization of $8.44 billion, a PE ratio of -14.40 and a beta of 2.64.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($2.72) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.83) by $0.11. bluebird bio had a negative net margin of 1,018.02% and a negative return on equity of 32.15%. The company had revenue of $19.20 million during the quarter, compared to analysts’ expectations of $9.06 million. During the same quarter last year, the company posted ($2.52) EPS. The firm’s revenue was up 357.1% compared to the same quarter last year. On average, sell-side analysts predict that bluebird bio Inc will post -11.81 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Voloridge Investment Management LLC Purchases New Holdings in bluebird bio Inc (BLUE)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/4240472/voloridge-investment-management-llc-purchases-new-holdings-in-bluebird-bio-inc-blue.html.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Further Reading: Liquidity

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$1.37 Billion in Sales Expected for Caci International Inc  This Quarter
$1.37 Billion in Sales Expected for Caci International Inc This Quarter
TokenStars Trading 26.8% Higher  This Week
TokenStars Trading 26.8% Higher This Week
Akoustis Technologies Inc  Expected to Post Earnings of -$0.25 Per Share
Akoustis Technologies Inc Expected to Post Earnings of -$0.25 Per Share
Selfkey  24-Hour Trading Volume Hits $967,433.00
Selfkey 24-Hour Trading Volume Hits $967,433.00
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd  This Quarter
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd This Quarter
Waves Community Token Trading 1.3% Higher  Over Last Week
Waves Community Token Trading 1.3% Higher Over Last Week


© 2006-2019 Ticker Report